Related Experiment Video

Updated: May 7, 2026

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model
09:57

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model

Published on: June 4, 2017

11.6K

Double suicide gene therapy using human neural stem cells against glioblastoma: double safety measures

Ji Yeoun Lee1, Do-Hun Lee, Hyung A Kim

  • 1Division of Pediatric Neurosurgery, Pediatric Clinical Neuroscience Center, Seoul National University Children's Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Republic of Korea.

Journal of Neuro-Oncology
|October 12, 2013
PubMed

Insights

This study developed a safer gene therapy for glioblastomas using neural stem cells (NSCs) with double prodrug enzymes. The engineered NSCs demonstrated effective tumor treatment and efficient self-elimination, enhancing safety for clinical use.

Area of Science:

  • Biomedical Engineering
  • Cancer Therapy
  • Neuroscience

Background:

  • Stem cell-based gene therapies offer promise but raise safety concerns, including immunological issues and oncogenesis.
  • Glioblastomas are aggressive brain tumors with limited treatment options.
  • Ensuring the safety of transplanted cells is crucial for clinical translation of gene therapies.

Purpose of the Study:

  • To investigate the therapeutic efficacy and safety of neural stem cells (NSCs) engineered to express double prodrug enzymes (cytosine deaminase and tyrosine kinase) for glioblastoma treatment.
  • To compare the efficacy of NSCs expressing double prodrug enzymes (HB1.F3-CD.TK) with those expressing a single prodrug enzyme (HB1.F3-CD).
  • To assess the safety of the double prodrug system by evaluating NSC elimination and proliferation.

Main Methods:

  • In vitro and in vivo studies comparing HB1.F3-CD.TK cells with HB1.F3-CD cells for glioblastoma treatment.
  • In vitro viability assays to measure NSC elimination after prodrug treatment.
  • In vivo analysis of NSC proliferation within tumors.

Main Results:

  • HB1.F3-CD.TK cells demonstrated comparable or superior therapeutic efficacy to HB1.F3-CD cells in both in vitro and in vivo models.
  • The HB1.F3-CD.TK cells exhibited the lowest in vitro viability post-prodrug treatment, indicating efficient elimination.
  • In vivo studies showed minimal proliferation of HB1.F3-CD.TK cells within the tumor microenvironment.

Conclusions:

  • Double-prodrug enzyme-directed gene therapy using engineered NSCs is a viable strategy for glioblastoma treatment.
  • This approach achieves effective tumor elimination while ensuring efficient eradication of the therapeutic NSCs, thereby enhancing safety.
  • The findings support the clinical application of stem cell-based gene therapies with improved safety profiles.

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

7.2K
Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds09:18

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Published on: July 16, 2018

7.7K

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
22.3K